首页> 外文期刊>Molecular therapy: the journal of the American Society of Gene Therapy >G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a
【24h】

G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a

机译:G6PC mRNA治疗可积极调节空腹血糖并降低糖原储存疾病的小鼠模型中的肝异常1A

获取原文
获取原文并翻译 | 示例
           

摘要

Glycogen storage disease type Ia (GSD1a) is an inherited metabolic disorder caused by the deficiency of glucose-6-phosphatase?(G6Pase). GSD1a is associated with life-threatening hypoglycemia and long-term liver and renal complications. We examined the efficacy of mRNA-encoding human?G6Pase in a liver-specific G6Pase?/?mouse model (L-G6PC?/?) that exhibits the same hepatic biomarkers associated with GSD1a patients, such as fasting hypoglycemia, and elevated levels of hepatic glucose-6-phosphate (G6P), glycogen, and triglycerides. We show that a single systemic injection of wild-type or native human G6PC mRNA results in significant improvements in fasting blood glucose levels for up to 7?days post-dose. These changes were associated with significant reductions in liver mass, hepatic G6P, glycogen, and triglycerides. In addition, an engineered protein variant of human G6Pase, designed for increased duration of expression, showed superior efficacy to the wild-type sequence by maintaining improved fasting blood glucose levels and reductions in liver mass for up to 12?days post-dose. Our results demonstrate for the first time the effectiveness of mRNA therapy as a potential treatment in reversing the hepatic abnormalities associated with GSD1a.
机译:糖原储存疾病IA(GSD1A)是由葡萄糖-6-磷酸酶的缺乏引起的遗传性代谢紊乱?(G6Pase)。 GSD1A与威胁性低血糖和长期肝脏和肾并发症有关。我们在肝脏特异性G6Pase中检测了mRNA编码的人的功效吗?肝葡萄糖-6-磷酸(G6P),糖原和甘油三酯。我们表明,单一的全身注射野生型或本地人G6PC mRNA导致血液血糖水平的显着改善,最高可达7.剂量持续7.天数。这些变化与肝脏肿块,肝脏G6P,糖原和甘油三酯的显着减少有关。此外,设计用于提高表达持续时间的人G6Pase的工程化蛋白变体,通过维持改善的空腹血糖水平和肝脏质量的降低至多12?天剂量,通过保持肝脏质量的降低至野生型序列的优异效果。我们的结果首次证明MRNA治疗的有效性作为逆转与GSD1A相关的肝异常的潜在治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号